| Name | Title | Contact Details |
|---|
Lily AI helps brands to see customers as they see themselves. The company is a women-founded startup headquartered in Mountain View, CA is backed by Canaan Partners, NEA, Fernbrook Management, Unshackled Ventures among others. Our customers range from big box stores to specialty brands, and full-line department stores to resale marketplaces.
We use the most advanced technologies on a proven platform to deliver intelligent applications for business across all sectors. Industry, Product and Salesforce experts.
Come see why Fandango is the go-to destination for more than 36 million moviegoers each month. Fandango helps movie fans discover, buy tickets and share their passion for movies in a more engaging and interactive way. Fandango entertains, informs and guides film fans with must-see trailers and movie clips, exclusive and original content, insider news and expert commentary. We make it easy to find and buy the right movie at the right time, with showtimes and ticketing to more than 26,000 screens nationwide. Fandango is available online, and through our award-winning mobile and connected television apps with over 46 million downloads and counting. We welcome movie fans on Facebook, Twitter, Instagram, Tumblr, Google+ and Pinterest.
Stride is a software company that automates phone, online, and dine-in orders for restaurants.
Juventas Therapeutics is a private clinical-stage company developing novel therapies for ischemic cardiovascular disease. The company`s lead product` JVS-100` is a non-viral plasmid that encodes for stromal cell-derived factor-1 (SDF-1). SDF-1 has been shown to significantly increase end-organ function following tissue injury by promoting cell survival` recruiting endogenous stem cells to the damaged region` and promoting new blood vessel growth. The SDF-1 repair pathway is well conserved throughout end-organ systems providing the opportunity to impact a broad range of diseases. Target cardiovascular clinical indications address large markets with high unmet medical need and significant market potential. Juventas is currently enrolling multiple clinical trials to test therapy efficacy in heart failure and critical limb ischemia patients.